Get the Stockscreener App
1.47
4.55%
-0.07
After Hours:
1.47
Fate Therapeutics Inc stock is traded at $1.47, with a volume of 1.50M.
It is down -4.55% in the last 24 hours and up +54.74% over the past month.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
See More
Previous Close:
$1.54
Open:
$1.52
24h Volume:
1.50M
Relative Volume:
0.78
Market Cap:
$169.53M
Revenue:
$13.45M
Net Income/Loss:
$-178.23M
P/E Ratio:
-0.8909
EPS:
-1.65
Net Cash Flow:
$-132.53M
1W Performance:
-10.09%
1M Performance:
+54.74%
6M Performance:
+32.43%
1Y Performance:
-54.35%
1-Day Range:
$1.445
$1.53
1-Week Range:
$1.30
$1.65
52-Week Range:
$0.6611
$3.50
Fate Therapeutics Inc Stock (FATE) Company Profile
Name
Fate Therapeutics Inc
Sector
Industry
Phone
858.875.1803
Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.47 | 177.61M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-24-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Jan-06-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-06-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-06-23 | Downgrade | Stifel | Buy → Hold |
| Jan-06-23 | Downgrade | Truist | Buy → Hold |
| Jan-06-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-15-22 | Initiated | Goldman | Sell |
| Nov-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jul-28-22 | Initiated | Needham | Hold |
| Jul-11-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-11-22 | Resumed | BMO Capital Markets | Market Perform |
| Dec-15-21 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Nov-09-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-07-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-07-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Jefferies | Buy |
| Feb-26-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-27-21 | Resumed | H.C. Wainwright | Neutral |
| May-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-09-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-30-19 | Reiterated | Mizuho | Buy |
| Dec-09-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-06-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Jun-07-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Mar-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-03-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-05-18 | Initiated | Jefferies | Buy |
| Aug-01-18 | Initiated | Citigroup | Buy |
| Mar-06-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
View All
Fate Therapeutics Inc Stock (FATE) Latest News
Why Fate Therapeutics Inc. stock remains a top recommendationGDP Growth & Technical Entry and Exit Alerts - newser.com
How Fate Therapeutics Inc. stock benefits from global expansionStop Loss & Short-Term High Return Strategies - newser.com
Analyzing drawdowns of Fate Therapeutics Inc. with statistical toolsAnalyst Downgrade & Reliable Price Action Trade Plans - newser.com
Is Fate Therapeutics Inc a good long term investmentInstitutional Holding Changes & Secret Picks Wall Street Isn’t Talking About - earlytimes.in
Using fundamentals and technicals on Fate Therapeutics Inc.Earnings Beat & Daily Market Momentum Tracking - newser.com
Is Fate Therapeutics Inc. stock reversal real or fakeMarket Movement Recap & Step-by-Step Trade Execution Guides - newser.com
Is Fate Therapeutics Inc. stock affected by interest rate hikesJuly 2025 Pullbacks & Weekly Top Gainers Alerts - newser.com
Published on: 2025-10-14 21:30:26 - newser.com
FATE appoints Kamal Adawi CFO as board reduces from 10 to 8 - Stock Titan
Fate Therapeutics, Inc. Appoints Kamal Adawi as Chief Financial Officer, Effective October 20, 2025 - MarketScreener
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer - GlobeNewswire
375,000-option grant leads Fate Therapeutics' appointment of Kamal Adawi as CFO, effective Oct 20, 2025 - Stock Titan
Automated trading signals detected on Fate Therapeutics Inc.Trade Exit Summary & Reliable Price Breakout Alerts - newser.com
Advanced analytics toolkit walkthrough for Fate Therapeutics Inc.Options Play & Community Driven Trade Alerts - newser.com
Published on: 2025-10-13 07:01:23 - newser.com
What technical signals suggest for Fate Therapeutics Inc. stockJuly 2025 Short Interest & AI Enhanced Execution Alerts - newser.com
What’s next for Fate Therapeutics Inc. stock priceWeekly Earnings Recap & High Win Rate Trade Alerts - newser.com
Risk vs reward if holding onto Fate Therapeutics Inc.July 2025 Review & Free Safe Capital Growth Stock Tips - newser.com
Historical volatility pattern of Fate Therapeutics Inc. visualizedEarnings Recap Summary & High Conviction Buy Zone Picks - newser.com
Real time social sentiment graph for Fate Therapeutics Inc.Trade Volume Report & Verified Entry Point Signals - newser.com
Fate Therapeutics (NASDAQ:FATE) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat
Fate Therapeutics, Inc. $FATE Stock Holdings Lessened by Public Employees Retirement System of Ohio - Defense World
Fate Therapeutics (NASDAQ:FATE) Stock Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
Is Fate Therapeutics Inc. stock in correction or buying zoneJuly 2025 Summary & Comprehensive Market Scan Reports - newser.com
Chart based analysis of Fate Therapeutics Inc. trendsMarket Activity Report & Real-Time Market Trend Scan - newser.com
Fate Therapeutics Inc. stock daily chart insightsPortfolio Performance Report & Weekly Breakout Stock Alerts - newser.com
What analysts say about Fate Therapeutics Inc stockPrice Gap Trading Strategies & Big Returns, Small Investment – Learn How - earlytimes.in
Detecting price anomalies in Fate Therapeutics Inc. with AI2025 Market Sentiment & Free Reliable Trade Execution Plans - newser.com
Is Fate Therapeutics Inc. stock trading at a premium valuationFed Meeting & Real-Time Buy Signal Alerts - newser.com
Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners may be pleased with recent gains after 62% loss over the past year - Yahoo Finance
Fate Therapeutics Reports New Employee Inducement Awards under Nasdaq Listing Rule 5635(4) - MarketScreener
Should you hold or exit Fate Therapeutics Inc. now2025 Market Sentiment & Reliable Intraday Trade Alerts - newser.com
Top chart patterns to watch in Fate Therapeutics Inc.July 2025 Price Swings & High Return Trade Guides - newser.com
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics reports new employee inducement awards under Nasdaq listing rule - MarketScreener
Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 62% over the previous year - simplywall.st
Fate Therapeutics Inc Stock (FATE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):